- Home Page
- » On-Demand CME Activities
- » Hematology-Oncology
- » Clinical Conversations in Multiple Myeloma Patient Management
Clinical Conversations in Multiple Myeloma Patient Management
Release date: November 2010
Expiration date: November 30, 2012
Estimated time to complete activity: 1.5 hours
Jointly sponsored by Curatio CME Institute, the Multiple Myeloma Research Foundation, and University of Wisconsin-Madison Continuing Education in Nursing
Support for this activity has been provided through educational grants from Celgene, Centocor Ortho Biotech, and Millennium: The Takeda Oncology Company.
- Active Internet connection
- Adobe Flash Player Plugin 8.0+
Statement of Need
Treatment options for patients with multiple myeloma are changing for all stages of the disease. Clinical data emerging from trials with newly introduced agents and new classes of agents indicate superior response rates, most notably complete response rates, and improved survival over traditional chemotherapy regimens. The rapidly evolving nature of treatment advances for multiple myeloma, coupled with the ongoing need to manage comorbidities and adverse effects of therapy, magnify the challenge to health care providers of delivering patient-tailored therapy. Oncology nurses who manage patients with multiple myeloma must be able to apply clinical data to complex, case-based scenarios, such as determining the appropriate course of action for patients with newly diagnosed or relapsed/refractory multiple myeloma who experience disease- and treatment-related side effects.
This activity is designed to provide oncology nurses with practice-changing information and skills that may minimize treatment- and disease-related complications in patients with multiple myeloma so as to limit dose-reductions or treatment discontinuations. The activity presents a series of video segments featuring clinical conversations on multiple myeloma that address practical, individualized management strategies for oncology nurses.
This activity has been designed to meet the educational needs of oncology nurses and other health care professionals involved in the care of patients with multiple myeloma.
Upon completion of this activity, participants should be able to:
- Describe the tests used to diagnose multiple myeloma
- Evaluate the clinical efficacy and safety of treatments for newly diagnosed and relapsed/refractory myeloma patients
- Describe the potential side effects with therapies for newly diagnosed and relapsed/refractory multiple myeloma patients
- Outline an optimal care plan for myeloma patients experiencing treatment-related side effects and disease-related complications
Tiffany Richards, RN, ANP-BC, NS
MD Anderson Cancer Center
Regina A. Swift, RN
Clinical Nurse Manager
James R. Berenson, MD, Inc.
West Hollywood, California
The University of Wisconsin-Madison Continuing Education in Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Iowa Provider Number: 350
This activity has been planned and implemented using the educational design criteria of the ANCC’s Commission on Accreditation through the joint providership of the University of Wisconsin-Madison Continuing Education in Nursing and the other providers; 1.5 ANCC Contact Hours (1.8 Iowa) will be awarded for successful completion of this activity based on documented participation and attainment of minimum score of 70% on posttest. Awarding of contact hours does not imply product endorsement.
Method of Participation
The estimated completion time is 90 minutes.
There are no fees for participating in this CE activity. To receive credit during the period November 2010 to November 30, 2012, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the posttest and activity evaluation form, including the certificate information section. No credit will be given after November 30, 2012.
Please e-mail any questions to firstname.lastname@example.org.
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
It is the policy of the University of Wisconsin-Madison Continuing Education in Nursing to ensure balance, independence, objectivity, and scientific rigor at all individually or jointly provided educational programs. All individuals who are in a position to influence the content of an educational activity are required to disclose all relevant (occurring within the past 12 months) financial, professional, and personal relationships with commercial interests relating to the topics of this educational activity in order to allow Continuing Education in Nursing staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during the educational activity. For this educational activity, all conflicts of interest have been resolved and detailed disclosures are listed below.
Tiffany A. Richards, RN, ANP-BC, MS, has disclosed the following relevant financial relationships:
|Consultant, Honorarium||Millennium, Celgene|
Ms. Richards discusses the unlabeled or investigational use of a commercial product.
Regina A. Swift, RN, has disclosed the following relevant financial relationships:
|Advisory Board/Consultant||Novartis, Millennium|
Ms. Swift discusses the unlabeled or investigational use of a commercial product.
Multiple Myeloma Research Foundation
Anne Quinn Young, MPH, Vice President, Communications, has disclosed no relevant financial relationships.
The University of Wisconsin-Madison Continuing Education in Nursing
LeaRae Galarowicz, MS, RN-BC, Clinical Professor and Director, has disclosed no relevant financial relationships.
Patricia Trapp, RN, MAE, has disclosed no relevant financial relationships.
Curatio CME Institute
Denise C. LaTemple, PhD, President, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Thomas Finnegan, PhD, Associate Medical Director, has disclosed no relevant financial relationships.
The information presented at this activity is for continuing nursing education purposes only and is not meant to substitute for the professional judgment of a nurse regarding management of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, the Multiple Myeloma Research Foundation, University of Wisconsin-Madison Continuing Education in Nursing, Celgene, Centocor Ortho Biotech, and Millennium: The Takeda Oncology Company do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, the Multiple Myeloma Research Foundation, University of Wisconsin-Madison Continuing Education in Nursing, Celgene, Centocor Ortho Biotech, and Millennium: The Takeda Oncology Company. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Policy on Privacy and Confidentiality
Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.